of Biochemistry and Biophysics Helen P
Disclosures: Ahmed Elhariri: Nothing to Disclose, Manal Hassan: Nothing to Disclose, Mazen ELsheikh: Nothing to Disclose, Ahmed El sabagh: Nothing to Disclose, Mohamad Ali Ibrahim: Nothing to Disclose, Megha Bhongade: Nothing to Disclose, sali albarouki: Nothing to Disclose, Anish Nayak: Nothing to Disclose, Youseph Karouni: Nothing to Disclose, Prasun Jalal: Nothing to Disclose 1132 REAL-WORLD OUTCOMES OF PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) COMPENSATED CIRRHOSIS AT A LARGE ACADEMIC REFERRAL CENTER Shadera Slatter 1 Jordan Guillot 1 Christopher Williams 1 Alexandre Watanabe 2 Eirum Chaudhri 2 Xiao Zhang 2 Gail Fernandes 2 Jin Ge 3 Vivek Rudrapatna 1 , 1 Bakar Computational Health Sciences Institute, University of California, San Francisco, 2 Merck & Co., Inc., Rahway, NJ, USA, 3 University of California, San Francisco Background: Epidemiologic data on MASH compensated cirrhosis patients and their disease progression are limited
Most cases of premature hair greying stem from factors unrelated to supplementation, such as genetics or lifestyle
Here is how VitaStir stacks up against some of the most popular compounded tirzepatide providers
